Tema Cardiovascular and Metabolics ETF Rating $33.20 +0.57 (+1.75%) (As of 11/1/2024 ET) Add Compare Share Share Ratings Stock AnalysisChartHeadlinesHoldingsOwnershipRatingsShort InterestTrends Tema Cardiovascular and Metabolics ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.HRTS Aggregate RatingModerate Buy2.78Holdings in HRTS have an aggregate rating of Moderate Buy based on 479 analyst ratings issued in the past year covering 38 companies (84.9% of the portfolio).HRTS Aggregate Price Target$52.3357.62% UpsideHigh Prediction$71.58Average Prediction$52.33Low Prediction$34.82Holdings in HRTS have an aggregate price target of $52.33 and a range of $34.82 to $71.58 covering 38 companies (84.9% of the portfolio).HRTS Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy13 Buy rating(s)Moderate Buy21 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Cardiovascular and Metabolics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 38 HRTS Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings7.92%AMGNAmgen$319.22-0.3%4.5954 of 5 stars2.50$333.50 4.5%24Earnings ReportDividend AnnouncementAnalyst ForecastAnalyst Revision5.49%LLYEli Lilly and Company$818.93-1.3%4.9073 of 5 stars2.84$1,009.00 23.2%19Earnings ReportDividend AnnouncementAnalyst ForecastAnalyst Revision5.29%ALNYAlnylam Pharmaceuticals$273.91+2.7%3.9488 of 5 stars2.75$294.50 7.5%24Analyst ForecastShort Interest ↑News Coverage4.97%VRTXVertex Pharmaceuticals$471.12-1.0%3.4636 of 5 stars2.48$492.50 4.5%29Upcoming EarningsAnalyst Forecast3.66%CRNXCrinetics Pharmaceuticals$56.69+1.3%3.052 of 5 stars2.91$68.55 20.9%11Negative News3.63%BBIOBridgeBio Pharma$25.48+8.8%4.5477 of 5 stars2.87$47.50 86.4%15Upcoming Earnings3.16%CYTKCytokinetics$51.82+1.6%4.2687 of 5 stars2.73$83.93 62.0%15Upcoming EarningsInsider SellingShort Interest ↓2.84%MDTMedtronic$90.07+0.9%4.726 of 5 stars2.44$95.36 5.9%162.73%REGNRegeneron Pharmaceuticals$843.60+0.6%4.8471 of 5 stars2.73$1,090.24 29.2%22Analyst ForecastAnalyst RevisionNews CoverageHigh Trading Volume2.66%MREOMereo BioPharma Group$4.28+1.7%1.7813 of 5 stars3.20$7.50 75.2%5Positive News2.51%MASIMasimo$144.22+0.1%3.3297 of 5 stars2.57$145.33 0.8%7Upcoming Earnings2.50%BSXBoston Scientific$83.62-0.5%4.8538 of 5 stars2.91$93.39 11.7%23Analyst Forecast2.50%IONSIonis Pharmaceuticals$38.76+1.0%4.1679 of 5 stars2.65$60.28 55.5%20Upcoming EarningsShort Interest ↓News Coverage2.24%GPCRStructure Therapeutics$41.140.0%1.7789 of 5 stars3.00$86.80 111.0%62.15%RAREUltragenyx Pharmaceutical$50.994.2691 of 5 stars2.92$85.08 66.9%13Upcoming Earnings2.12%MIRMMirum Pharmaceuticals$40.40+5.0%4.5647 of 5 stars3.17$56.82 40.6%12Upcoming EarningsNews Coverage2.10%MLYSMineralys Therapeutics$13.45+0.5%2.7719 of 5 stars3.00$30.00 123.0%3Upcoming EarningsAnalyst ForecastNews Coverage2.05%ASNDAscendis Pharma A/S$125.28+2.0%3.0734 of 5 stars2.92$195.92 56.4%13Upcoming Earnings2.04%RCKTRocket Pharmaceuticals$16.98+2.0%4.3151 of 5 stars2.90$51.75 204.8%10Upcoming Earnings2.03%KROSKeros Therapeutics$59.94+3.3%3.4249 of 5 stars3.00$89.11 48.7%11Upcoming EarningsShort Interest ↓Positive News2.01%PODDInsulet$235.61+1.8%4.5248 of 5 stars2.79$242.29 2.8%14Upcoming EarningsNews Coverage1.98%DXCMDexCom$70.35-0.2%4.9945 of 5 stars2.72$104.59 48.7%18Analyst Downgrade1.94%EWEdwards Lifesciences$67.54+0.8%4.6338 of 5 stars2.38$75.67 12.0%26Analyst DowngradeShort Interest ↓Analyst RevisionNews Coverage1.59%NTLAIntellia Therapeutics$14.81+4.1%4.2672 of 5 stars2.76$59.13 299.3%171.59%ARWRArrowhead Pharmaceuticals$19.49+1.4%4.2511 of 5 stars2.70$45.33 132.6%10News Coverage1.32%AKROAkero Therapeutics$32.33+4.9%3.9016 of 5 stars2.86$43.20 33.6%7Insider SellingPositive News1.31%WSTWest Pharmaceutical Services$316.50+2.8%4.8952 of 5 stars2.67$460.33 45.4%3Insider Selling1.13%SLNSilence Therapeutics$17.68+2.2%2.7473 of 5 stars3.00$57.20 223.5%51.02%MDGLMadrigal Pharmaceuticals$319.58+23.2%3.9348 of 5 stars2.69$344.33 7.7%13Earnings ReportAnalyst ForecastNews CoverageGap UpHigh Trading Volume0.98%EWTXEdgewise Therapeutics$34.00+1.3%1.983 of 5 stars3.00$35.60 4.7%5Short Interest ↓Positive News0.96%SLNOSoleno Therapeutics$55.86+1.5%4.3012 of 5 stars3.13$69.86 25.1%8Upcoming Earnings0.94%NARIInari Medical$48.74+0.7%3.1996 of 5 stars2.45$58.89 20.8%11Analyst ForecastInsider SellingAnalyst Revision0.94%VKTXViking Therapeutics$72.88+0.5%4.1533 of 5 stars3.09$108.60 49.0%110.71%TERNTerns Pharmaceuticals$6.94+1.2%4.6125 of 5 stars2.83$26.92 287.8%6Analyst ForecastNews Coverage0.69%VERVVerve Therapeutics$5.93+3.5%2.3492 of 5 stars3.00$26.00 338.4%5Upcoming Earnings0.48%CRBPCorbus Pharmaceuticals$16.92+6.0%4.4642 of 5 stars3.13$65.86 289.2%8Upcoming EarningsShort Interest ↑0.40%TNYATenaya Therapeutics$1.94+1.0%3.1245 of 5 stars3.00$15.25 686.1%7Gap Up0.30%RANIRani Therapeutics$2.31+0.9%3.1035 of 5 stars3.14$11.71 407.1%7Gap Up This page (NASDAQ:HRTS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Cardiovascular and Metabolics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Cardiovascular and Metabolics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
